Celularity (CELUW) Non-Current Debt (2024 - 2025)

Celularity (CELUW) reported Non-Current Debt of $36.5 million for Q2 2025, little changed quarter-over-quarter from $36.5 million in Q1 2025.

Celularity (CELUW) Non-Current Debt (2024 - 2025) Analysis & Trends

Celularity (CELUW) has 2 years of Non-Current Debt data on file, last reported at $36.5 million in Q2 2025.

Non-Current Debt for Q2 2025 came in at $36.5 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $36.5 million (changed N/A YoY), and the FY2024 annual result was $35.9 million, changed N/A from the prior year.
Non-Current Debt steadied at $36.5 million in Q2 2025 per CELUW's latest filing, from $36.5 million in the prior quarter.
Over five years, Non-Current Debt peaked at $36.5 million in Q1 2025 and troughed at $35.9 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	319.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Celularity	-	-	-3.27 Mn	-

Download Data